ARTICLE | Clinical News
XiDay bromfenac regulatory update
January 4, 2010 8:00 AM UTC
Ista submitted an sNDA to FDA for once-daily XiDay bromfenac to treat ocular inflammation and pain following cataract surgery. Ista markets a twice-daily formulation of 0.09% bromfenac as Xibrom for ...